Peptides for injury recovery: a primer

Peptides come up in almost every online injury-recovery conversation, and the two names that appear most often are BPC-157 and TB-500. Both have real preclinical support for tissue-repair effects. Neither has cleared a randomised controlled trial in humans for any orthopaedic indication^[1]. This primer explains what each peptide is, what the evidence actually shows, and what you should know before pursuing either one.

This article does not provide dosing protocols. No validated human dose-response data exists for either peptide in an injury-recovery context, and providing a number would misrepresent the state of the evidence.

BPC-157: what the preclinical record shows

BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice, first characterised by researchers at the University of Zagreb in 1991. Its preclinical record across soft-tissue injuries is one of the stronger ones in the grey-market peptide space. Animal studies have reported accelerated healing of transected Achilles tendons, medial-collateral-ligament injuries, and segmental muscle damage. The proposed mechanisms centre on angiogenesis (new blood-vessel growth into the injured area), modulation of VEGF and basic FGF signalling, and influence over the nitric-oxide system that governs vascular response to injury.

A 2026 review in Sports Medicine by Mendias and Awan examined the evidence base for approved and unapproved peptides in musculoskeletal injuries. The authors concluded that many unapproved peptides, including BPC-157, show "favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients"^[1]. A separate 2026 review in the American Journal of Sports Medicine by Mayfield and colleagues confirmed the animal signal for tendon and muscle repair but noted the results remain "largely unvalidated in human trials"^[2]. No published Phase 2 or Phase 3 randomised controlled trial of BPC-157 for any orthopaedic indication exists.

The angiogenic mechanism is particularly relevant to tendons and ligaments, which are hypovascular tissues. Limited blood supply is one reason these injuries heal slowly and why a compound that promotes vessel growth into damaged tissue would, in theory, accelerate repair. That theoretical plausibility is part of what drives interest. It does not substitute for a characterised human dose and safety profile.

TB-500: a different molecule with overlapping claims

TB-500 is used as a trade label for two distinct molecules: a synthetic seven-amino-acid heptapeptide (AC-LKKTETQ, sometimes called the fragment), and full-length thymosin beta-4 (a 43-amino-acid protein naturally found in most mammalian cells). The published academic literature uses the term thymosin beta-4 or Tβ4; the athletic and injury-recovery community uses TB-500. Vendors do not always specify which molecule is in the vial.

Thymosin beta-4 is the major G-actin sequestering protein in mammalian cells, meaning it controls how much free actin is available for cell migration and tissue remodelling. Reviews by Goldstein, Hannappel and Kleinman (2005) and Philp and Kleinman (2010) document effects on dermal wound healing, corneal repair, and cardiac protection in rodent and large-animal models^[3]. A 2026 orthopaedic review classified both BPC-157 and TB-500 as wound-healing peptides promoting angiogenesis and fibroblast activation, while concluding that "there is a current lack of clinical trials"^[4].

The only human trial data for the parent molecule sits in ophthalmology. A Phase 3 trial of a thymosin beta-4 ophthalmic solution (RGN-259) for neurotrophic keratopathy reported positive corneal healing outcomes, but this is a topical formulation tested on a specific tissue type. It does not generalise to injectable TB-500 for tendon or ligament repair in humans.

Regulatory and safety status

Neither BPC-157 nor TB-500 is approved by the FDA, EMA, MHRA, or any national medicines agency in the countries PeptideMethods covers. Both circulate through grey-market research-chemical channels. The US Department of Defense's Operation Supplement Safety programme has explicitly labelled BPC-157 as "an unapproved drug" with "little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans"^[5]. The FDA has cautioned against compounded drugs containing BPC-157 due to safety risks.

Both peptides are prohibited in competitive sport. BPC-157 sits on the WADA Prohibited List under S0 (non-approved substances), banned in and out of competition. TB-500 is prohibited under WADA section S2 (peptide hormones, growth factors and related substances). USADA states that because BPC-157 has not been extensively studied in humans, "no one knows if there is a safe dose, or if there is any way to use this compound safely." See the BPC-157 regulation page and the TB-500 regulation page for jurisdiction-specific detail.

Grey-market supply introduces a second layer of risk. Independent testing of vials sold online has found purity failures, mislabelled products, and contamination above pharmaceutical limits. A vial labelled TB-500 may contain the short heptapeptide, full-length Tβ4, neither, or both, because vendors often do not specify and identity testing is rare.

What the evidence gap means in practice

The preclinical rationale for both peptides in soft-tissue injury recovery is real and reasonably well described across multiple published reviews. The human evidence is absent for orthopaedic use. That gap matters because animal results do not reliably predict human outcomes at equivalent doses, and because the translation requires dose-finding, safety profiling, and controlled efficacy trials that have not been completed for either compound in this context^[2].

If you are researching peptides because you have a soft-tissue injury that is not responding to standard care, the conversation starts with the clinician or physiotherapist managing your rehabilitation. They can recommend interventions with a characterised human evidence base. The information on this page is for understanding what the research does and does not support, not for guiding a personal protocol.

What we do not yet know

For BPC-157: no published work establishes a human therapeutic dose range, characterises long-term safety, or examines interactions with surgical hardware or concurrent medications. For TB-500: we do not know whether the short AC-LKKTETQ fragment reproduces the tissue effects of full-length Tβ4 in humans, and no systemic injection trial outside ophthalmology has been completed. For both: the quality of any individual grey-market vial is unknown without batch-level mass-spectrometry identity testing, which is not routine in that supply chain.